{"id":"NCT03823404","sponsor":"Cortexyme Inc.","briefTitle":"GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease","officialTitle":"GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-03-28","primaryCompletion":"2022-01-01","completion":"2022-01-01","firstPosted":"2019-01-30","resultsPosted":"2023-02-23","lastUpdate":"2023-02-23"},"enrollment":643,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"COR388 capsule","otherNames":["atuzaginstat"]},{"type":"DRUG","name":"Placebo capsule","otherNames":["atuzaginstat"]}],"arms":[{"label":"COR388 80 mg twice daily (BID)","type":"EXPERIMENTAL"},{"label":"COR388 40 mg BID","type":"EXPERIMENTAL"},{"label":"Placebo BID","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD) dementia.","primaryOutcome":{"measure":"Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)","timeFrame":"Baseline to Week 48","effectByArm":[{"arm":"COR388 80 mg BID (Twice Daily)","deltaMin":23.7,"sd":8.8},{"arm":"COR388 40 mg BID (Twice Daily)","deltaMin":23.4,"sd":8.6},{"arm":"Placebo BID (Twice Daily)","deltaMin":23.6,"sd":9.3}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.0455"}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":93,"countries":["United States","France","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":214},"commonTop":["diarrhea","urinary tract infection","ALT increased","AST increased","headache"]}}